QuickLinks -- Click here to rapidly navigate through this document
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
June 14, 2004
DYAX CORP.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization) | | 000-24573
(Commission file number) | | 04-3053198
(IRS employer
identification number) |
300 Technology Square, Cambridge, MA 02139
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code:
(617) 225-2500
Item 5. Other Events.
On June 14, 2004, Dyax Corp. issued a press release announcing that its Phase II clinical trial of DX-88 for treatment of hereditary angioedema met its primary endpoint. A copy of that press release is attached as Exhibit 99.1.
Item 7. Financial Statements,Pro Forma Financial Information and Exhibits.
- (c)
- Exhibits.
- 99.1
- Press release of Dyax Corp. dated June 14, 2004.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | DYAX CORP. |
Dated: June 14, 2004 |
|
By: |
|
/s/ STEPHEN S. GALLIKER
Stephen S. Galliker
Executive Vice President, Finance and Administration, and Chief Financial Officer |
3
EXHIBIT INDEX
Exhibit No.
| | Description
|
|---|
| 99.1 | | Press release of Dyax Corp. dated June 14, 2004. |
QuickLinks
SIGNATUREEXHIBIT INDEX
